- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02142127
Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers
An Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labelled GFT505 and Its 14C-Metabolites) and to Investigate the Metabolic Profile and Pharmacokinetics of GFT505
Human mass-balance studies with radiolabelled study drug are needed to evaluate the amount of drug that is recovered over time via different elimination routes of the body, i.e., whole blood, blood cells, plasma, urine, feces, and expired air. The ideal case is to be able to demonstrate a (near) complete recovery (≥95 %) of the administered dose.
A good understanding of the metabolic pathway of the study drug is equally important. Mass-balance data, together with metabolic profiles in excreta, are used to characterize the biotransformation pathways of a drug and to help evaluate its drug-drug interaction potential.
To this purpose, in this study, blood, urine, and feces are collected to investigate the metabolic profile of GFT505, and plasma and urine are collected to investigate the non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007. Other metabolites will be investigated in plasma and urine according to the radioactivity results. Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.
Study Overview
Detailed Description
This is a Phase I open-label, single oral dose and single center study of 14C-labelled GFT505 and its metabolites in healthy subjects.
After an overnight fast, subjects will be administered one dose of 14C-labelled GFT505 containing an equivalent of 120 mg of the compound with 240 mL of non-carbonated water. The total amount of administered radiocarbon will be 1.63-1.81 megaBecquerel (MBq) (44.1-48.8 μCi).
Blood, urine, and feces will be collected at scheduled time intervals from before administration of the radiolabelled study drug throughout confinement at the clinical center and thereafter, if needed. Several samples of expired carbon dioxide will be obtained up to 48 h after the administration of radiolabelled study drug.
Radiocarbon will be assayed in all available samples (whole blood, plasma, urine, feces, and expired air) by liquid scintillation spectrometry. The metabolic profile of GFT505 will be assayed in plasma, urine, and feces. Non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007 will be assayed in plasma and urine. Other metabolites will be investigated in plasma and urine according to the radioactivity results. Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Life Science Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Caucasian males aged 55 to 65 years inclusive
- Body Mass Index (BMI) ≥ 18 ≤ 30 kg/m²
- Fitzpatrick skin type < 4
- No clinically relevant abnormalities in hematology and clinical chemistry parameters, blood pressure (BP) and heart rate (HR) (supine), or ECG results
Exclusion Criteria:
- History or presence of any hepatic, renal, respiratory, cardiovascular, neurologic, gastrointestinal, endocrine, immunologic, musculoskeletal, or hematologic disorder capable of altering the absorption, metabolism, or elimination of drugs, or capable of constituting a risk factor when taking the study drug, as judged by the investigator;
- Creatinine Clearance as calculated by the Cockcroft-Gault formula less than 60 mL/min;
- History of irregular bowel movements such as regular episodes of diarrhea, constipation (less than a mean of one bowel movement per day) or irritable bowel movement;
- Planning to become a father or to donate sperm within 3 months after the administration of study drug;
- History or presence of drug addiction (positive drug screen for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, or opiates) or excessive use of alcohol (daily intake exceeding 2 units/day);
- Current use of nicotine containing products, i.e., more than 5 cigarettes or equivalent/day and the inability to stop using nicotine containing products during confinement in the clinical center;
- Large caffeine consumption (daily average of more than 6 cups of coffee or tea or more than 1L of caffeine-containing beverages) within the last year;
- Plasma levels of ALT, AST, or alkaline phosphatase (ALP) ≥1.5 x upper limit of laboratory normal range (ULN);
- Blood donation or loss of significant amount of blood within 12 weeks prior to dosing;
- Inability to understand the constraints of full urine and stool collection or inability to collect urine;
- Use of any drug treatment that could affect the outcome of the study from 14 days before the administration of the radiolabelled study drug (2 months for enzyme-inducing drugs) or 5 times the half-life of the medication, or anticipated use of concomitant therapy (except paracetamol) during the study;
- Exposure to ionizing radiations (except routine or dental radiography or radiography of the extremities), including participation in studies with radiolabelled compounds, or exposure to radioisotopes within one year prior to entry into the present study;
- Participation in another clinical study within 12 weeks prior to entry into the present study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 14C-labelled GFT505 120 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Excretion balance of radiocarbon in whole blood, blood cells, plasma, urine, feces, and expired air after a single oral dose of 14C-labelled GFT505.
Time Frame: 0-19 days
|
Blood, urine, and feces will be collected at scheduled time intervals from before administration of the radiolabelled study drug throughout confinement at the clinical center and thereafter, if needed. Several samples of expired carbon dioxide will be obtained up to 48 h after the administration of radiolabelled study drug. Radiocarbon will be assayed in all available samples (whole blood, plasma, urine, feces, and expired air) by liquid scintillation spectrometry. |
0-19 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic profile of GFT505 in plasma, urine, and feces.
Time Frame: 0- 19 days
|
The metabolic profile of GFT505 will be assayed in plasma, urine, and feces.
Non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007 will be assayed in plasma and urine.
Other metabolites will be investigated in plasma and urine according to the radioactivity results.
Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.
|
0- 19 days
|
Safety parameters
Time Frame: 0 - 19 days
|
Safety assessment will be based on adverse events (AEs), clinical laboratory tests, electrocardiogram (ECG), vital signs, and physical examination.
|
0 - 19 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Sophie Megnien, MD, Chief Medical Officer, Genfit
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GFT505-114-10
- 2014-000958-10 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Lancaster UniversityRecruiting
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on 14C-labelled GFT505 120 mg
-
IpsenRecruitingPrimary Sclerosing CholangitisUnited States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
-
GenfitCompletedPrimary Biliary Cholangitis (PBC)United States, United Kingdom, France, Germany, Spain
-
Hoffmann-La RocheChugai Pharmaceutical Co.TerminatedNeuromyelitis Optica Spectrum Disorder | NMOSDUnited States, Korea, Republic of, Italy, Canada, Japan, Turkey
-
Eli Lilly and CompanyActive, not recruitingNeoplasms, HematologicUnited States, Germany, Australia, Sweden, France, Spain, Italy, Austria, Canada
-
PfizerCompletedHealthy VolunteerNetherlands
-
AstraZenecaCompletedMajor Depressive DisorderUnited Kingdom
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeUnited Kingdom
-
AlbireoCompletedPrimary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver DiseasesUnited Kingdom
-
Galapagos NVCompletedHealthyUnited Kingdom
-
Hutchison Medipharma LimitedCompleted